Business Growth and success

Increase the number of molecules studiedThe number of molecules derived from internal R & D of pharmaceutical companies beingusually not enough, they strive to acquire shares in the market, either bythrough licensing or through acquisitions.Demand is currently so strong that sales of licenses that are no longerthe form of betting, and the molecules are not necessarily offered interesting:the head of an average company recently told me that after reviewing one hundredpresentation folders license, he had retained a single molecule.The other way to obtain new molecules is to acquire companies. Weobserved that the binding does not occur only from groupsbuy pharmaceutical biotechnology companies, but also between them.The current enthusiasm for biotechnology comes from the observation that the number of moleculesderived from biotechnology is growing.Through these efforts, the number of molecules studied by the industry has not increasednegligible in recent years, and these new molecules currently in phase twoand three, are likely to result in a greater number of medications alsoactually put on the market in the coming years.Cost reductionThe second is that of cost reduction. For this, we first seek to betteridentify, as early as possible, the molecules that will not survive. A study bythe Tufts Center for the Study of Drug Development found that the primary cause of failure isobservation that the new molecule is more effective than existing drugs. Thesecond is a lack of profitability, which may be related to unexpected developments in themarket. The third is a toxicology too high, that is to say the side effects notanticipated too great.Companies are developing methods to better predict the likelihood of success of anew product. This often does a better integration of functions and strategyCorporate Marketing, to remove early stage products that will not cost asufficient. It became such a very ambitious strategy of developingnot only a new molecule, but beyond, to create a new class of drugs(First in class) had extremely high risks. Many companies prefernow target molecules that do not constitute a new therapeutic class, butare more effective than existing products (best in class). Similarly, manyprojects do not provide sufficient differentiation in the market (me too) are scarcelyprofitable businesses and thus eliminate more and more such projects.Given the weight of financial expenses related to the duration of the investment required before themarketing, a second axis to reduce costs is to reduce the timedevelopment. Finally, manufacturers are trying to enhance the effectiveness of clinical studies toreduce the cost per patient. Some use it for outsourcing, and we seedevelopment of companies specializing in clinical trials under contract. The company KingPharmaceuticals pushed this reasoning to the extreme. It manages 15 projects, but uses only65 employees and has no laboratory: everything is managed under contract, and R & D doesrepresents only 2% of its turnover.Another method of reducing costs is to outsource clinical trials incountries where these tests can be made in economic conditions over